Mixed Dyslipidemia - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Mixed Dyslipidemia - Pipeline Review, H1 2016', provides an overview of the Mixed Dyslipidemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mixed Dyslipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mixed Dyslipidemia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Mixed Dyslipidemia - The report reviews pipeline therapeutics for Mixed Dyslipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Mixed Dyslipidemia therapeutics and enlists all their major and minor projects - The report assesses Mixed Dyslipidemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Mixed Dyslipidemia Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Mixed Dyslipidemia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Mixed Dyslipidemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Mixed Dyslipidemia Overview 6 Therapeutics Development 7 Pipeline Products for Mixed Dyslipidemia - Overview 7 Mixed Dyslipidemia - Therapeutics under Development by Companies 8 Mixed Dyslipidemia - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Mixed Dyslipidemia - Products under Development by Companies 12 Mixed Dyslipidemia - Companies Involved in Therapeutics Development 13 Amgen Inc. 13 CymaBay Therapeutics, Inc. 14 Hanmi Pharmaceuticals, Co. Ltd. 15 Matinas BioPharma Holdings, Inc. 16 Pfizer Inc. 17 Thetis Pharmaceuticals LLC 18 Mixed Dyslipidemia - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 bococizumab - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 evolocumab - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 HCP-1105 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 IONIS-ANGPTL3LRx - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 MAT-9001 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 MBX-8025 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 TP-452 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Mixed Dyslipidemia - Recent Pipeline Updates 39 Mixed Dyslipidemia - Dormant Projects 55 Mixed Dyslipidemia - Discontinued Products 56 Mixed Dyslipidemia - Product Development Milestones 57 Featured News & Press Releases 57 May 24, 2016: New study results show cholesterol-lowering medication, Repatha (evolocumab), lowers LDL-C when self-administered in at-home setting 57 Apr 01, 2016: Pfizer Announces Positive Topline Results From Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab 58 Mar 16, 2016: Amgen Wins Patent Case On Repatha (Evolocumab) 58 Nov 18, 2015: NICE issues draft guidance on evolocumab for lipid disorder 59 Mar 30, 2014: Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins 60 Mar 29, 2014: New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol By 55-66 Percent Compared To Placebo In Patients With High Cholesterol 63 Dec 19, 2013: Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab In Patients With High Cholesterol 65 Appendix 68 Methodology 68 Coverage 68 Secondary Research 68 Primary Research 68 Expert Panel Validation 68 Contact Us 68 Disclaimer 69
List of Tables
Number of Products under Development for Mixed Dyslipidemia, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Mixed Dyslipidemia - Pipeline by Amgen Inc., H1 2016 13 Mixed Dyslipidemia - Pipeline by CymaBay Therapeutics, Inc., H1 2016 14 Mixed Dyslipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 15 Mixed Dyslipidemia - Pipeline by Matinas BioPharma Holdings, Inc. , H1 2016 16 Mixed Dyslipidemia - Pipeline by Pfizer Inc., H1 2016 17 Mixed Dyslipidemia - Pipeline by Thetis Pharmaceuticals LLC, H1 2016 18 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Stage and Target, H1 2016 21 Number of Products by Stage and Mechanism of Action, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 25 Number of Products by Stage and Molecule Type, H1 2016 27 Mixed Dyslipidemia Therapeutics - Recent Pipeline Updates, H1 2016 39 Mixed Dyslipidemia - Dormant Projects, H1 2016 55 Mixed Dyslipidemia - Discontinued Products, H1 2016 56
List of Figures
Number of Products under Development for Mixed Dyslipidemia, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Clinical Stage Development, H1 2016 10 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Targets, H1 2016 20 Number of Products by Stage and Targets, H1 2016 20 Number of Products by Mechanism of Actions, H1 2016 22 Number of Products by Stage and Mechanism of Actions, H1 2016 22 Number of Products by Routes of Administration, H1 2016 24 Number of Products by Stage and Routes of Administration, H1 2016 24 Number of Products by Molecule Types, H1 2016 26 Number of Products by Stage and Molecule Types, H1 2016 26
Europe industrial air filtration market size is projected to reach USD 1,690.8 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing implementation in various industries such as metal, cement and food & beverages among otRead More...
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Global electric water heaters market is expected to be valued at USD 29,322.4 million by 2022, as per a new research report by Radiant Insights, Inc. Escalating demand across extensive range of domestic applications is expected to drive demand. EvolvRead More...
Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expectedRead More...
Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global demRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.